DK2742356T3 - Prædiktorer til cancerbehandling - Google Patents

Prædiktorer til cancerbehandling Download PDF

Info

Publication number
DK2742356T3
DK2742356T3 DK12754124.1T DK12754124T DK2742356T3 DK 2742356 T3 DK2742356 T3 DK 2742356T3 DK 12754124 T DK12754124 T DK 12754124T DK 2742356 T3 DK2742356 T3 DK 2742356T3
Authority
DK
Denmark
Prior art keywords
predictor
lymphoma
treatment
biomarker
pfs
Prior art date
Application number
DK12754124.1T
Other languages
English (en)
Inventor
Deborah Ricci
Erin Devay Henitz
Weimin Li
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2742356T3 publication Critical patent/DK2742356T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)

Claims (8)

1. Fremgangsmåde til at prognosticere respons for en cancerbehandling omfattende bortezomib og rituximab hos en non-Hodgkin's lymfomcancerpatient, omfattende: bestemme niveauet eller mængden af en første prædiktor i en biologisk prøve fra denne patient, hvor den første prædiktor er CD68 eller PSMB1 (P11A) polymorfisme; og bestemme tilstedeværelsen eller mængden afen anden prædiktor i denne patient; hvor lav CD68 eller tilstedeværelse af PSMB1 (P11A) polymorfisme korreleres med mindst ét positivt udfald, og tilstedeværelse, fravær, eller mængde af den anden prædiktor korreleres med mindst ét positivt udfald.
2. Fremgangsmåden ifølge krav 1, hvor den første prædiktor er lav CD68, såsom hvor lav CD68 er 50% eller derunder CD68-positive celler, som bestemt ved immunohistokemi.
3. Fremgangsmåden ifølge krav 1, hvor den første prædiktor er PSMB1 (P11A) polymorfisme.
4. Fremgangsmåden ifølge krav 1, hvor den anden prædiktor er valgt fra gruppen bestående af: lav CD68, PSMB1 (P11A) polymorfisme, PSMB5 (R24C) polymorfisme, alder på under 65, én tidligere behandling, lav Follikulær Lymfom International Prognostic Index (FLIPI) score, og lav tumorbyrde.
5. Fremgangsmåden ifølge krav 1, hvor non-Hodgkin's lymfom er follikulær B-celle-non-Hodgkin's lymfom.
6. Anvendelse af et diagnostisk kit eller ækvivalent til at identificere non-Hodgkin's lymfom-patienter der er kandidater til en særlig cancerbehandling omfattende bortezomib og rituximab omfattende: et reagens der påviser mængden eller tilstedeværelse afen første prædiktor i en biologisk prøve; et reagens der påviser mængden eller tilstedeværelse af en anden prædiktor i en biologisk prøve; og instruktioner til anvendelse af indikatorerne til at identificere patienter der er kandidater til denne behandling; hvor den første prædiktor er valgt fra gruppen bestående af CD68 og PSMB1 (P11A) polymorfisme.
7. Anvendelsen ifølge krav 6, hvor den anden prædiktor er valgt fra gruppen bestående af CD68, PSMB1 (P11A) polymorfisme og PSMB5 (R24C) polymorfisme.
8. Anvendelsen ifølge krav 6, hvor non-Hodgkin's lymfom er follikulær B-celle-non-Hodgkin's lymfom.
DK12754124.1T 2011-08-11 2012-08-08 Prædiktorer til cancerbehandling DK2742356T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522596P 2011-08-11 2011-08-11
US201161560555P 2011-11-16 2011-11-16
PCT/US2012/049941 WO2013022935A1 (en) 2011-08-11 2012-08-08 Predictors for cancer treatment

Publications (1)

Publication Number Publication Date
DK2742356T3 true DK2742356T3 (da) 2016-05-23

Family

ID=47668910

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12754124.1T DK2742356T3 (da) 2011-08-11 2012-08-08 Prædiktorer til cancerbehandling

Country Status (20)

Country Link
US (1) US9322066B2 (da)
EP (1) EP2742356B1 (da)
JP (1) JP6002222B2 (da)
CN (1) CN103930785B (da)
AU (1) AU2012294493B2 (da)
CA (1) CA2844825A1 (da)
CY (1) CY1117838T1 (da)
DK (1) DK2742356T3 (da)
ES (1) ES2586328T3 (da)
HK (2) HK1199094A1 (da)
HR (1) HRP20160851T1 (da)
HU (1) HUE029295T2 (da)
MX (1) MX357429B (da)
PL (1) PL2742356T3 (da)
PT (1) PT2742356E (da)
RS (1) RS55053B1 (da)
RU (1) RU2600026C2 (da)
SI (1) SI2742356T1 (da)
SM (1) SMT201600235B (da)
WO (1) WO2013022935A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130346111A1 (en) * 2012-06-22 2013-12-26 Quintiles Transnational Corporation Systems and Methods for Subject Identification (ID) Modeling
US10795879B2 (en) 2012-06-22 2020-10-06 Iqvia Inc. Methods and systems for predictive clinical planning and design
EP3164506A4 (en) * 2014-07-01 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
WO2016037283A1 (en) * 2014-09-10 2016-03-17 Litens Automotive Partnership Proportionally damped power transfer device using torsion spring force
EP3471752B1 (en) * 2016-06-17 2022-03-09 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
US11598403B2 (en) 2017-03-28 2023-03-07 Litens Automotive Partnership Isolation device with selected angle between spring stop and damping member
EP3705584A1 (en) * 2019-03-05 2020-09-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method of identifying patients with bortezomib resistant multiple myeloma and other blood diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
CA2435124A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
ES2542328T3 (es) * 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
CN100366636C (zh) * 2004-12-08 2008-02-06 中国农业科学院畜牧研究所 猪生产及免疫性状相关蛋白，它的编码基因与应用
KR100653990B1 (ko) 2004-12-29 2006-12-05 주식회사 하이닉스반도체 포토마스크 데이터베이스 패턴의 불량 검사 방법
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
EP2046973A4 (en) 2006-08-10 2010-04-07 Millennium Pharm Inc METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY
US20100086922A1 (en) 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment

Also Published As

Publication number Publication date
HUE029295T2 (en) 2017-02-28
EP2742356B1 (en) 2016-04-27
ES2586328T3 (es) 2016-10-13
SI2742356T1 (sl) 2016-06-30
CA2844825A1 (en) 2013-02-14
AU2012294493A1 (en) 2014-02-20
PT2742356E (pt) 2016-06-06
JP6002222B2 (ja) 2016-10-05
RS55053B1 (sr) 2016-12-30
AU2012294493B2 (en) 2017-02-23
HRP20160851T1 (hr) 2016-09-23
CY1117838T1 (el) 2017-05-17
US9322066B2 (en) 2016-04-26
PL2742356T3 (pl) 2016-11-30
EP2742356A1 (en) 2014-06-18
CN103930785A (zh) 2014-07-16
JP2014524571A (ja) 2014-09-22
CN103930785B (zh) 2016-05-18
HK1199094A1 (en) 2015-06-19
HK1199097A1 (zh) 2015-06-19
MX2014001619A (es) 2014-11-10
WO2013022935A1 (en) 2013-02-14
RU2014108986A (ru) 2015-09-20
US20130216524A1 (en) 2013-08-22
MX357429B (es) 2018-07-09
RU2600026C2 (ru) 2016-10-20
SMT201600235B (it) 2016-08-31

Similar Documents

Publication Publication Date Title
DK2742356T3 (da) Prædiktorer til cancerbehandling
JP7323393B2 (ja) ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
US11725247B2 (en) Methods of treating cancer
EP3601355A1 (en) Methods of treating tumor
Kapoor et al. Waldenström macroglobulinemia: What a hematologist needs to know
JP2023118967A (ja) 腫瘍変異負荷
US20150110779A1 (en) Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
EP3978629A1 (en) Prediction of an outcome of a bladder or kidney cancer subject
EP4093513A1 (en) Uses of biomarkers for improving immunotherapy
Hodkinson et al. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
JP2023500950A (ja) マントル細胞リンパ腫（ｍｃｌ）対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法
JP7571872B2 (ja) 膀胱がん又は腎臓がん対象者の転帰の予測
Boyle The genetic architecture of plasma cell disorders
Fernández-Hinojal Prognostic capacity of peripheral blood-derived biomarkers in NSCLC patients treated with PD-1/PD-L1 blockade immunotherapy
Bacchiarri Comprehensive Evaluation of PD-L1, BCL-2 by Next-Generation Flow Analysis and FISH Abnormalities of Aberrant Plasma Cells in Patients Affected by Smoldering Multiple Myeloma